Blood cancer patients with autoimmune conditions face dramatically worse outcomes when receiving life-saving stem cell transplants, challenging current treatment protocols that may inadequately account for immune system complexity. This finding could reshape how oncologists evaluate transplant candidacy for thousands of patients annually.
Analysis of 161 myelodysplastic syndrome patients revealed those with pre-existing autoimmune diseases experienced significantly higher cancer relapse rates and reduced leukemia-free survival compared to matched controls. The autoimmune cohort also showed impaired platelet recovery following transplantation, suggesting compromised bone marrow regeneration. Patients with active autoimmune disease at transplant time faced the poorest outcomes, with markedly elevated relapse risk.
This represents the first substantial evidence quantifying transplant risks in this vulnerable population, filling a critical knowledge gap in hematologic oncology. The immune dysregulation characterizing autoimmune conditions appears to create a hostile environment for transplant success, potentially through chronic inflammatory pathways that promote cancer cell survival or impair donor cell engraftment. Current transplant protocols largely ignore autoimmune history when assessing patient risk profiles, despite this cohort representing roughly 25% of blood cancer patients. The findings suggest intensive pre-transplant immune modulation or alternative conditioning regimens may be necessary for autoimmune patients. However, the retrospective design and relatively small autoimmune cohort limit generalizability. Prospective trials incorporating autoimmune status into risk stratification models are essential to develop evidence-based treatment modifications that could improve outcomes for this high-risk population.